UTHR Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$369.96 |
| 52 Week High | US$374.73 |
| 52 Week Low | US$208.62 |
| Beta | 0.57 |
| 11 Month Change | 7.24% |
| 3 Month Change | 12.56% |
| 1 Year Change | 60.64% |
| 33 Year Change | 92.42% |
| 5 Year Change | 339.49% |
| Change since IPO | 5,971.14% |
Recent News & Updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27
United Therapeutics: Economics Support Compounding Ability
Aug 20Recent updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17Shareholder Returns
| UTHR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 3.5% | 1.2% |
| 1Y | 60.6% | 26.7% | 35.4% |
Return vs Industry: UTHR exceeded the US Biotechs industry which returned 21.6% over the past year.
Return vs Market: UTHR exceeded the US Market which returned 32.2% over the past year.
Price Volatility
| UTHR volatility | |
|---|---|
| UTHR Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: UTHR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| UTHR fundamental statistics | |
|---|---|
| Market cap | US$16.00b |
| Earnings (TTM) | US$1.07b |
| Revenue (TTM) | US$2.62b |
15.4x
P/E Ratio6.3x
P/S RatioIs UTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTHR income statement (TTM) | |
|---|---|
| Revenue | US$2.62b |
| Cost of Revenue | US$291.80m |
| Gross Profit | US$2.32b |
| Other Expenses | US$1.26b |
| Earnings | US$1.07b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.04 |
| Gross Margin | 88.85% |
| Net Profit Margin | 40.87% |
| Debt/Equity Ratio | 8.8% |
How did UTHR perform over the long term?
See historical performance and comparison